HbA1c News and Research

RSS

Closed-loop artificial pancreas system improves diabetes management in adolescents

Research shows that the use of an artificial pancreas system helps to compensate for omission and underestimation of insulin boluses in adolescents with Type 1 diabetes.

1 Dec 2014

No added benefit proven for empagliflozin in type 2 diabetes

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

21 Nov 2014

EKF Molecular Diagnostics to present at AMP annual meeting

EKF, announces that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology.

From EKF Diagnostics 6 Nov 2014

EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that its CE Mark for the Maestro Rechargeable (RC) System for obesity was expanded to include the management of Type 2 diabetes mellitus through improved glycemic control.

29 Sep 2014

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes.

18 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glucose lowering may significantly reduce the risk of ischaemic heart disease in at-risk middle-aged people with Type 2 diabetes, a post-hoc analysis of the ACCORD trial suggests.

5 Sep 2014

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes.

4 Sep 2014

Diet reduces inflammatory markers in ‘real world’ Type 2 diabetes

Encouraging patients newly diagnosed with Type 2 diabetes to diet or to diet and increase their physical activity reduces markers of inflammation and their cardiovascular risk compared with usual care, real-world study findings show.

15 Aug 2014

Almonds can help reduce inflammation in people with poorly controlled diabetes

Evidence continues to mount supporting the role of almonds and other tree nuts as part of an overall dietary pattern that is beneficial for those with type 2 diabetes. Three new studies suggest a relationship between regular consumption of tree nuts, such as almonds, and improvement in various markers of health in type 2 diabetes.

12 Aug 2014

Inadequate management common in young-onset Type 2 diabetes

Patients with young-onset Type 2 diabetes have worse metabolic control than those with late-onset disease, but they are less likely to receive organ-protective drugs, show data from the Joint Asia Diabetes Evaluation cohort.

8 Aug 2014

New, promising approach combines metformin and SGLT2 inhibitors to treat diabetes

Various active substances in oral antidiabetic agents are frequently combined in the treatment of diabetes in order to achieve an effective reduction in the blood sugar. A new, very promising approach combines the substances metformin and SGLT2 inhibitors, the latter were just approved in 2012.

4 Aug 2014

Metformin and SGLT2 inhibitors together reduce blood sugar levels

Metformin and SGLT2 inhibitors together reduce the blood sugar levels considerably more effectively than either drug alone.

4 Aug 2014

Salt poses cardiovascular risk in diabetic patients

A diet high in salt increases the risk of cardiovascular disease in patients with Type 2 diabetes, show data from the Japan Diabetes Complications Study.

1 Aug 2014

Tree nuts have positive impact on glycemic control in diabetes and on metabolic syndrome criteria

Two new meta-analyses involving tree nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts) were recently published in the online publications, British Medical Journal Open (BMJ Open) and PLOS ONE.

1 Aug 2014

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone).

30 Jul 2014

Researchers recommend low carbohydrate diet for Type 1 and Type 2 diabetes

A new study involving researchers from the University of Alabama at Birmingham and other institutions says patients with Type 1 and Type 2 diabetes should eat a diet low in carbohydrates.

25 Jul 2014

Education boosts glycaemic control after diabetes diagnosis

Attending a brief diabetes education programme enhances the glycaemic control achieved by patients newly diagnosed, research suggests.

15 Jul 2014

Diabetes easier to control with insulin pump than self-injections?

Insulin pump therapy may be an effective alternative for people who cannot control their diabetes effectively using daily self-injections, show study findings.

3 Jul 2014

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.

28 Jun 2014